TORONTO & BETHESDA, Md.–(BUSINESS WIRE)–Today, Analytics for Life, a leading innovator in advanced point-of-care diagnostics, and CorVista Health, pioneers in non-invasive cardiac diagnostics, announced a publication of a new comprehensive cost economic analysis of their non-invasive point-of-care test for Coronary Artery Disease (CAD) in the Journal of Visualized Experiments (JoVE). “We […]
Other News
Investor Insights: Darshana Zaveri – What Stage Does Catalyst Typically Invest?
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2024 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.
Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced it will present one-year clinical outcomes from the 2,400 patient INFINITY-SWEDEHEART Randomized Clinical Trial (RCT), a prospective, multi-center, single-blind, clinical trial comparing the drug-eluting DynamX Coronary Bioadaptor System with the contemporary Resolute OnyxTM zotarolimus drug-eluting stent […]
Radiaction Medical Establishes Medical Advisory Board
TEL AVIV, Israel–(BUSINESS WIRE)–Radiaction Medical, LTD (“Radiaction”), a medical device company, has announced the formation of its U.S. Medical Advisory Board (MAB). The MAB will provide invaluable counsel and expertise to the company’s executive team, bolstering Radiaction’s mission to deliver comprehensive radiation protection to all medical staff involved in interventional […]
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
August 12, 2024 04:01 PM Eastern Daylight Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette has been appointed […]
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™
Rivus Pharmaceuticals’ Phase 2a HuMAIN Trial Meets Primary Endpoint of Weight Loss and Secondary Endpoints in Patients with Obesity-Related Heart Failure
– Data from the HuMAIN study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) will be presented in a Late Breaking Clinical Trial Plenary Session at the Heart Failure Society of America Annual Scientific Meeting – – Enrollment completed in Phase 2…
Boston Scientific to Participate in Wells Fargo’s 2024 Healthcare Conference
MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo’s 2024 Healthcare Conference on Wednesday, September 4, 2024. Mike Mahoney, chairman and chief executive officer, and Dr. Brad Sutton, chief medical officer, Atrial…
Humacyte Second Quarter 2024 Financial Results and Business Update
-FDA requires additional time to complete its review of ATEV™ (acellular tissue engineered vessel) BLA for the Treatment of Vascular Trauma-
Recent
Accelerating Adoption of AI Reporting in Radiology Has Propelled Replacement of Legacy SR Integration Technology
FDA Grants Coredio Breakthrough Designation for AI Platform Bringing Advanced Heart Failure Assessment Beyond the Hospital
BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
Popular
- No commented posts yet